Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Merck
Baxter
Colorcon
Boehringer Ingelheim

Last Updated: May 26, 2022

ERAXIS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Eraxis patents expire, and when can generic versions of Eraxis launch?

Eraxis is a drug marketed by Vicuron Holdings and is included in one NDA.

The generic ingredient in ERAXIS is anidulafungin. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the anidulafungin profile page.

Summary for ERAXIS
Drug patent expirations by year for ERAXIS
Drug Prices for ERAXIS

See drug prices for ERAXIS

DrugPatentWatch® Estimated Generic Entry Opportunity Date for ERAXIS
Generic Entry Date for ERAXIS*:
Constraining patent/regulatory exclusivity:
NEW PATIENT POPULATION
NDA:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ERAXIS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Texas Tech University Health Sciences CenterPhase 4
University of Texas Southwestern Medical CenterPhase 4
National Center for Research Resources (NCRR)Phase 4

See all ERAXIS clinical trials

US Patents and Regulatory Information for ERAXIS

ERAXIS is protected by zero US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ERAXIS is See Plans and Pricing.

This potential generic entry date is based on NEW PATIENT POPULATION.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

FDA Regulatory Exclusivity protecting ERAXIS

NEW PATIENT POPULATION
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ERAXIS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 See Plans and Pricing See Plans and Pricing
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 See Plans and Pricing See Plans and Pricing
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 See Plans and Pricing See Plans and Pricing
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 See Plans and Pricing See Plans and Pricing
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ERAXIS

See the table below for patents covering ERAXIS around the world.

Country Patent Number Title Estimated Expiration
Israel 105048 CYCLIC PEPTIDE ANTIFUNGAL AGENTS AND PROCESS FOR PREPARATION THEREOF See Plans and Pricing
Japan 4936595 See Plans and Pricing
European Patent Office 0561639 Dérivés cyclopeptidiques antifongiques et procédé de leur préparation (Cyclic peptide antifungal agents and process for preparation thereof) See Plans and Pricing
Hungary T63637 See Plans and Pricing
Australia 689391 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ERAXIS

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0561639 SPC002/2008 Ireland See Plans and Pricing SPC002/2008: 20081105, EXPIRES: 20180317
0561639 08C0009 France See Plans and Pricing PRODUCT NAME: ANIDULAFUNGINE; REGISTRATION NO/DATE: EU/1/07/416/001 20070920
0561639 91406 Luxembourg See Plans and Pricing 91406, EXPIRES: 20180318
0561639 SPC/GB08/016 United Kingdom See Plans and Pricing PRODUCT NAME: ANIDULAFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/416/001 20070920
0561639 300334 Netherlands See Plans and Pricing 300334, 20130318, EXPIRES: 20180317
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Merck
Dow
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.